Request for Applications From Graduate Students & Post-Doctoral Fellows

Request for Applications From Graduate Students & Post-Doctoral Fellows 2014 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 1 of 17

1. General The National Network of Excellence in Neuroscience (hereinafter: "NNE") was established in 2013 by Teva Pharmaceutical Industries Ltd. (hereinafter: "Teva") in order to support and enhance Israeli neuroscience research, with relevance to human neurological and psychiatric illness and to further strengthen the capabilities of the Israeli Neuroscience research community. The NNE focus is on research performed in accredited academic and medical institutions in Israel that excel in academic research on specific research pre-defined fields. Within the scope of the 2014 NNE, Teva shall provide research grants, to fund research efforts, (hereinafter Research Grant ) to selected outstanding (1) students registered in Israel for a Ph.D. program (hereinafter: "Pre-Doctoral") and (2) post-doctoral fellows that are registered for a fellowship in Israel that are within three (3) years of their doctorate (hereinafter: "Post-Doctoral"). The purpose of this request for applications (hereinafter: "RFA") is to present the NNE 2014 program, process and criteria for selecting research projects (hereinafter Research Projects ), reflected in the applicant research proposal ( Research Proposal ), that will be accepted into the NNE in 2014/5. Pre-Doctoral students and Post-Doctoral fellows are hereby invited to submit applications for NNE 2014 ( Applications ) to receive a Research Grant in support of their research as further described under this RFA. Teva will not publish a RFA for Principal Investigators lead Research Collaborations in 2014. 2. NNE Program Goals 2.1. Strengthening neuroscience research in Israel and enhancing Israel's standing as a world leader in neuroscience research; 2.2. Promoting existing efforts to attract world-class Israeli neuroscience scientists back to Israel; 2.3. Creating a critical mass of excellence in neuroscience research by supporting it in academic and medical research institutions in Israel; 2.4. Encouraging Israeli academic innovation, translational research and treatment in the field of neuroscience; 2.5. Strengthening multi-institutional partnerships to advance neuroscience research in Israel; 2.6. Promoting diversity in Israel by supporting the advancement of all sectors in the population of Israel that deals with neuroscience research; The program's objectives as stated above will serve as guidelines in the definition of criteria used during the evaluation and selection process of the NNE participants. 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 2 of 17

3. Areas of Neuroscience Research 3.1. The therapeutic areas of neuroscience research that the NNE will focus on are: 3.1.1. Neurodegenerative disorders, such as: Multiple Sclerosis (MS), Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Huntington's Disease, Amyotrophic lateral sclerosis (ALS) 3.1.2. Pain 3.1.3. Neuropsychiatric disorders, such as: Depression, Schizophrenia 3.1.4. Other Neurological disorders such as: Epilepsy, Tourette syndrome, Rett Syndrome and Duchenne muscular dystrophy. 3.2. Research areas that will be supported by the NNE 2014 such as: Disease genetics, Biomarkers, Animal models, Disease Pathways, Targets and Validated Targets, Bioinformatics, Novel approaches to disease modification, Discovery and early Preclinical drug development, in vitro, animal (in vivo) and basic neuroscience. 3.3 NNE 2014 will give special consideration to Pre-Doctoral or Post-Doctoral Research Proposals in the areas of: BBB enabling technologies, PMP, late stage pre-clinical studies. 4. Neuroscience Pre-Doctoral or Post-Doctoral Research Grants 4.1. Research Proposals could only be submitted by Pre-Doctoral or Post-Doctoral in academic or medical (e.g. hospitals, HMOs) institutions in Israel with research programs in neuroscience (hereinafter "Institution"). 4.2. As applicable, the Institution will be responsible for obtaining any certificates of approval and/or authorizations required to conduct the research and present such certificate to Teva prior to the commencement of the research. 4.3. Research Proposals for a Research Grant should be submitted by the Pre-Doctoral or Post-Doctorate applicant, as applicable, in the areas of neuroscience described in Section 3, and must include the endorsement of the Principal Investigator and its Institution. Pre- Doctoral can apply for Research Grant, not to exceed $25,000 and Post-Doctoral can apply for Research Grants, not to exceed $35,000. Teva's support will be for one year only starting from contract signing date. 4.4. Research Grant applications ( Applications ) will be submitted in accordance with the guidelines and application form in Appendix A Neuroscience Grant Application Form. 4.5. Applicants for Research Grants ( Applicants ) must be Israeli citizens and/or permanent residents or returning Israeli citizens with granted study and/or work positions at Institutions. 4.6. The Research Proposal will be selected based on an internal process which includes Teva's considerations in accordance with the process described in Section 5.4 below. 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 3 of 17

4.7. The Research Grant will be provided in support of the Research Project as appears in details in Appendix A and shall be used against the direct costs of such Research Project including the personnel (part or full time) cost for conducting the Research Project. In addition, up to $5,000 of the Research Grant may be used by the Pre-Doctoral or Post- Doctoral as applicable, to attend a scientific conference in order to present the progress or the results of the Research Project. For clarity, any use of the Research Grant for activities or expenses not related to the Research Project is strictly prohibited. All payments made as part of a Research Grant will be made to Institution and not to the selected Pre-Doctoral or Post Doctoral (in each case the Grantee ). 4.8. The Research Grant will not include support of educational programs (in Israel or abroad) aside of the participation in a conference as mentioned above in 4.7. 4.9. The selected recipients of the Research Grants (hereinafter Grantees ) must openly disclose the fact that Teva is providing them with Research Grant. 4.10. Past recipients of Teva NNE 2013 PhD Scholarships or Post-Doctoral Fellowships are not eligible to apply for NNE 2014 program. 5. Application Process and Guidelines 5.1. Guidelines for Submission of Research Proposals and Applications 5.1.1. Research Proposals and Applications shall be submitted in English and shall include the information requested in Appendix A. 5.1.2. Full Research Proposals and Applications, and any requests for clarifications and/or questions throughout the application process, shall be sent by email to the contact person listed in Section 5.3 below. 5.2. This RFA will be managed according to the following process and timeline: # Phase Details Due Date 1 RFA Issuance Issuance of this RFA to Institutions and in public communications 3 Proposal Submissions Last date for applicants to submit their proposals to Teva 4 Announcement Teva will announce the recipients and issue acceptance/rejection letters November 30 th 2014 January 30 th, 2015 March 1 st, 2015 5.3. Contact Person Teva contact person for all purposes regarding this RFA is: 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 4 of 17

First and Last Name: Dr Guy Rosenthal Position: Manager, Global Academia Affairs and R&D Networks Direct Phone: +972-3-9148534 Mobile: +972-50-7581221 Email: guy.rosenthal@teva.co.il Address: Teva NNE Program, Global R&D, Basel 16, Petach Tiqva 5.4. Evaluation and Selection Process 5.4.1. All Applications and Research Proposals for Research Grants will be reviewed, evaluated and selected by a committee nominated by Teva and chaired by the President of Teva Global R&D and CSO. 5.4.2. The following criteria will be considered while evaluating and selecting the Grantees: Degree of scientific excellence and coherence of the Application; Degree of scientific innovation and the translational potential to lead significant medical advances; Relevance to diagnostics and/or therapeutics applications Credentials of the applicant(s); Development of highly qualified research skills and methods ; Degree of multi-institutional collaboration and sharing of knowledge, expertise, and resources; The expected contribution to the sustainable growth of neuroscience research in the State of Israel; Degree of promoting diversity in Israel by supporting the advancement in various sectors of Israeli population in neuroscience research from different Institutions; 5.4.3. Notwithstanding anything to the contrary in this RFA, Teva shall have the sole discretion in selecting Applications and reserves the right to accept or reject any and all responses at its sole discretion. Accordingly, the criteria specified in Section 6.4.2 are intended solely to provide certain information to the Applicants as to the selection process of the Research Proposals but Teva shall have the right to assign any degree of importance to each such criteria and even deviate from such criteria, if it deems advisable. 5.4.4. Grantees declare that, at all relevant times, whether prior, during or after the conduct of the research, all necessary certification requirements will be met in accordance with policies and regulations on ethical conduct of research. 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 5 of 17

5.4.5. A Final progress report will be submitted to Teva by the Grantees in accordance with instructions provided by Teva. The Progress Report should be up to 15 pages in length including: Project Information Research Overview Research Objectives Research Mile-Stones Research Progress Status Discussion Conclusions and Future Plans 5.4.6. All Grantees will participate in NNE events and/or meetings such as the annual meeting of the NNE to be organized by Teva. It is expected that Grantees will be invited for 3-4 events during 2015. These events and the requested participation of the Grantees are required in order to promote the objectives of the NNE 2014 as detailed in section 2. 6. The Agreement Teva and the Grantees of the Research Grants, their respective participating Institutions and their respective Principal Investigators shall sign the Research Grant agreement attached herewith as Appendix B (hereinafter: "Agreement"). The Agreement will be signed, in addition to the Grantee, by the Institution and the Principal Investigator who are accountable for the conducting of the Research Project and to ensure that the Research Grant is used in compliance with the agreement and this RFA. The Agreement, will contains sections regarding Teva's right to request and review the progress of the research activities and Teva's right to request a reconciliation of the funds in case that the Pre-Doctoral or Post-Doctoral Fellow left the Institution or stopped conducting the research for any reason whatsoever. By submitting an Application in accordance with this RFA, the Applicants and the Institution are accepting all terms and conditions set forth in this RFA and the Agreement. Where there is a contradiction between this RFA and the Agreement, the Agreement shall prevail. 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 6 of 17

APPENDIX A TO THE RFA PRE-DOCTORAL & POST--DOCTORAL RESEARCH GRANT APPLICATION FORM PART I 1. Research Project Title (NNE will identify your project according to the Project Title) 2. Name of institution(s) (Institution that will administer the funds for your project) 3. Principal Investigator 4. Name of Pre-Doctoral and Post- Doctoral Fellow 5. Summary of the Research Project (up to 300 words) 6. Therapeutic Area PART II 7. Short description of the overall research program (up to 4 pages) which shall include the following information: a. Scientific background and definition of the proposed research including a short review of existing research in the field. b. Defined research objectives c. Rationale d. Program description e. Research methodology f. Relevance to therapeutic development g. Significance h. Collaboration with other Institutions PART III 8. Schedule and work-plan (up to 1 page) Outline of timetable (research major milestones and expected completion dates for each), for accomplishing the research objectives stated above. To include the following parameters: a. Research Activity b. Institution c. Department d. Beginning (month, year) e. End (month, year) 9. Detailed annual budget for the research project (up to 1 page): a. The total grant request should not exceed $25,000 for Pre-Doctoral or $35,000 for Post- Doctoral, as applicable. Budget activity and justification b. Research Grants must be forward looking and may not compensate expenses already occurred by the Grantee. 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 7 of 17

PART IV 10. Applicant's declaration of approval from relevant authorities: Applicant must indicate which approvals are required for the proposed research and which have already been obtained, and status of those still pending. (There is no need to include the documentation in the application unless specifically requested to by Teva.) PART V 11. Curriculum Vitae of all participating applicants, which shall include the following: a. Name (Title, Last, First, Initial) b. Birth Year c. Proof of residence in Israel and/or Proof of Israeli citizenship d. Institution and Department e. Institution mail address f. Phone no (office) g. Fax h. E-mail i. Educational Background (years, institution, specialization, degree) j. Major Fields of Interest k. Employment History (years, institution, area of research, title) l. List of Publications by Applicant (year of publication, title of publication, institution, field of publication) m. List of Grants received by Applicant in past three (3) years (year(s), title of project, Source, Total Grant amount in USD) n. List of Awards received by Applicant (year, title of award, source) 12. Institution a. Institutions administrative contact (name, email and tel.) b. Institution's Official approval c. Principal Investigator personal liability approval 13. Requirements for all attachments to the Application: a. Attachments must be uploaded in PDF format b. Margin of 2 cm (minimum) around the page c. Observe page limitations, additional pages may NOT be added unless specified d. Use only letter size (21.25 X 27.5 cm) white paper/background for all attachments e. Photo-reduce the supporting documents if the originals are larger than (21.25 X 27.5 cm) f. Use a font size of 12 point, black type. No condensed type or spacing. 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 8 of 17

APPENDIX B TO THE RFA RESEARCH AGREEMENT RESEARCH GRANT AGREEMENT ("Agreement") by and between TEVA PHARMACEUTICAL INDUSTRIES LTD a company incorporated in accordance with the laws of Israel of 5 Bazel Street, Petah Tiqva 49131, Israel ( Teva ) And ("Institution") On behalf of itself and on behalf of ("Student") and ("Investigator") (the Student,Investigator and the Institution may be refered to to jointly as the "Researcher") Teva and Researcher each shall be referred to herein as a Party and together as the Parties WHEREAS Student has been awarded by Teva with a Research Grant, as defined in the Request for Applications of the National Network of Excellence in Neuroscience (hereinafter: "RFA"), to conduct research, under the supervision of the Investigator, in accordance with the research plan and budget attached hereto as Annex A (the Research and "Research Plan" respectively), and in accordance with the terms and conditions hereinafter set forth; and WHEREAS Teva desires to support the Research as part of the National Network of Excellence in Neuroscience (hereinafter: "NNE") more particularly described herein. NOW THEREFORE THE PARTIES AGREE AS FOLLOWS: 1. OBLIGATIONS OF THE RESEARCHER 1.1. The Student shall perform the Research in accordance with the Research Plan, this Agreement and with all applicable laws, regulations and requirements. 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 9 of 17

1.2. Where applicable, Institution will be responsible for obtaining any certificates of approval and/or authorizations required to conduct the Research and present such certificate to Teva prior to the commencement of the Research. 1.3. Any change to the Research Plan, including the Budget (as defined below), shall be subject to the prior written approval of Teva which may be withheld for any or no reason. 1.4. In the event of a conflict between the terms of this Research Grant Agreement and the RFA, the terms of this Research Grant Agreement shall govern. 1.5. The Research shall be carried out by the Student, under the direction and supervision of the Investigator who shall have responsibility for the scientific and technical conduct of the work on behalf of the Student and the Institution. 1.6. Upon Teva s request, Researcher shall provide Teva with a written progress report of activities completed and funds used, until the day of such report. In the event that the Research Grant, or any part thereof, was not used in accordance with the Research Plan, the Parties shall negotiate in good faith regarding the allocation of such funds in accordance with the applicable law and in accordance with Teva s policies. Such report cannot be required by Teva more than once during the Term. 1.7. In addition, no later than sixty (60) days following the earlier of (i) completion of the Research or (ii) termination or expiration of this Research Agreement, Researcher shall provide Teva with a final written report of the results of the performed Research (the "Final Report"). The Final Report shall include details, methods and procedures, all data with statistical analysis, experimental detail, the summary of the significance of the Research findings and any other detail as agreed in the Research Plan. 2. RESEARCH GRANT; BILLING 2.1. Teva shall provide the Research Grant as per the budget in the Research Plan (the "Budget").To avoid any doubt, the Budget is definite and represents the entire consideration for the performance of the Research. Furthermore, the sums to be paid pursuant to the Budget are final and inclusive of all taxes and/or duties, of whatsoever nature, which are now or may hereafter be imposed with regard to the this Research Agreement or any other document related to this document, for which the Researcher shall be solely liable. For clarity, the Research Grant represents the direct cost of the Research. Institution hereby agrees not to collect any indirect costs or overheads from the Research Grant. 2.2. The Institution shall invoice Teva as per the Budget within thirty (30) days of the Effective Date. Payment shall be made within sixty (60) days after the last day of the month of the receipt and approval of the invoice and following deduction of any withholding taxes, levies and/or any other taxes or duties as may be required by 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 10 of 17

applicable law. All payments shall be made in US Dollars to the credit of such bank account as may be designated in writing by Institution. 2.3. The parties agree that an amount of up to five thousand USD ($5,000) of the Budget may be used by the Student for attending scientific conferences in order to present the Research or the Research Results (defined below). Such participation will be subjected to local laws and requirements including any internal requirements that the university applies on such participation, and it is the student responsibility to obtain such approvals. In addition, the scientific conference must be held in appropriate locations and venues that are conducive to scientific exchange of information, and Teva's funding must be limited to the payment of travel, meals, accommodations and registration fees. The student should inform Teva prior attending the conference and will provide Teva with proof of attendance within a reasonable period of time after attending the conference. For clarity, this Research Grant may not support other educational programs (in Israel or abroad) except as mentioned herein. 3. TITLE & INTELLECTUAL PROPERTY 3.1. All right, title and interest in and to all and any inventions, know-how, methods, processes, techniques, software, algorithms, devices, products, materials, compounds, compositions, substances, data, information, findings and other results of whatsoever nature, created, generated, discovered, reduced to practice and/or arising in the course of and/or from the performance of the Research (collectively, the Research Results ); and all patent applications covering portions of the Research Results and all patents which may be granted thereon (the a foregoing patent applications and patents, collectively, the Patents ) vest and shall vest in the Institution. 4. CONFIDENTIALITY 4.1. The parties undertake to treat and to maintain in confidence any Confidential Information (as defined below) disclosed by either Party or its affiliates to the other Party or its affiliates under this Research Agreement. Each Party shall not disclose or use the other Party's Confidential Information other than for the purposes of this Research Agreement, including, the exercise of any rights hereunder or in the fulfillment of any obligations hereunder. The receiving Party shall treat the disclosing Party's Confidential Information with the same degree of care and confidentiality that it maintains or protect its own confidential information, but in any event, no less than a reasonable degree of care. 4.2. Notwithstanding the foregoing, the receiving Party may disclose the Confidential Information of the disclosing Party: (i) to its affiliates, employees, agents, consultants or subcontractors who have a need to know such information for the exercise of the receiving Party's rights hereunder or in the fulfillment of its obligations hereunder; and (ii) to the extent required to be disclosed under any law, rule, regulation, court, or order 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 11 of 17

of any competent authority, provided that, to the extent reasonably possible, it shall notify the disclosing party thereof in order to enable that party to seek an appropriate protective order or other reliable assurance that confidential treatment will be accorded to such information, and such disclosure shall be made to the minimum extent required. 4.3. For purposes of this Research Agreement, Confidential Information means, with respect to a Party, any and all know-how, proprietary information and technology, including trade secrets, inventions, developments, discoveries, methods, techniques, formulations, data, results, reports, improvements and other information, whether or not patentable, whether disclosed in writing, orally or by any other means. Provided, however, the such information was not (i) known to the receiving Party at the time it was disclosed, other than by previous disclosure by or on behalf of the disclosing Party; (ii) is in the public domain at the time of disclosure or becomes part of the public domain thereafter other than as a result of a violation by the receiving Party or any of its employees, agents, consultants or subcontractors of the confidentiality obligations herein; (iii) is lawfully and in good faith made available to the receiving Party by a third party; or (iv) is independently developed by the receiving Party without the use of or reference to information. 4.4. In the event that Teva organizes any conference related to the NNE and/or the Research Grant, the Student undertakes to treat and maintain in confidence any designated confidential information disclosed by any third party in connection thereto and the provisions of this Article 4 shall apply respectively. 4.5. The confidentiality and non-use undertakings in this Section 4 above shall continue in effect during the term of this Research Agreement and for a period of 3 (three) years following termination of this Research Agreement. 5. PUBLICATION 5.1. Researcher may freely published the Research Results provided however that Researcher will ensure that each proposed publication or disclosure shall be submitted to Teva for its review at least thirty (30) days prior to the earlier of the date of submission to any journal or conference proceedings for review or the date of disclosure. 5.2. Where applicable, Researcher shall delete from its proposed publication, prior to submission, any Teva s Confidential Information that Teva identifies and requests to delete within the thirty (30) day review period. 5.3. In all publications, credit shall be given to Teva for supporting the Research. 6. TERMINATION 6.1 This Research Agreement shall be effective from the date of signature of the last signing party to the Agreement ("Effective Date") and shall continue in force and effect until the later of (a) the first anniversary of the Effective Date or (b) the completion of the 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 12 of 17

Research (the Term ) unless earlier terminated in accordance with the provisions of this Article 6. 6.2 If the Student leaves the Institution, or otherwise ceases to perform the Research for any reason whatsoever (the Departure Event ), Institution will notify Teva promptly after it became aware of such Departure Event and no later than thirty (30) days following such Departure Event, and this Agreement shall be terminated immediately. 6.3 If the Investigator ceases to supervise the Research for any reason whatsoever, Institution will notify Teva promptly and no later than thirty (30) days following such event, and Institution shall endeavor to find another investigator to supervise the Research. Teva shall continue supporting the Research only as long as Institution finds another investigator to supervise the Research who is willing to assume upon himself/herself the Investigator s obligations hereunder. For clarity, in the absence of such substitute Investigator for a period of more than forty five (54) days from the day Investigator ceases to supervise the Research, Teva may terminate this agreement immediately. 6.4. In the event that either Party commits a material breach of its obligations under this Agreement and fails to cure that breach within thirty (30) days after receiving a written demand to cure from the non-breaching Party, the non-breaching Party may terminate this Agreement immediately upon written notice of termination to the breaching Party. 6.5. The following provisions, as well as any rights, obligations and duties which by their nature extend beyond the expiration or termination of this Agreement, shall survive the expiration or termination of this Agreement: Section 1.10, 6.5, 6.6, 13.1, 15.1 as well as Articles 4 and 5. 6.6 In case of an early termination of this Agreement in accordance with this Article 6 (except for termination due to material breach by Teva), Teva shall have the right to request from Institution reconciliation of the Research Grant. In such case, Institution will remit to Teva, on a pro-rata basis, the amount paid in excess of the actual cost incurred by the Institution for this Research. 7. NO WARRANTIES 7.1. It is agreed that nothing in this Research Agreement shall constitute a representation or warranty by the Researcher, express or implied, that any results will be achieved by the Research or that the results or any part thereof are or will be commercially exploitable or of any other value and, Researcher furthermore makes no warranties and representations, express or implied, whatsoever as to the Research and any results of the Research, including implied warranties of non-infringement, merchantability or fitness for a particular purpose. 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 13 of 17

8. LIABILITY 8.1. Neither Party, nor its affiliates, will be liable for any loss, claim, damage, or expense, of whatsoever kind or nature, which may arise from or in connection with the Research. 9. NO AGENCY RELATIONSHIP 9.1. Nothing contained in this Research Agreement shall be construed to place either the Researcher or Teva in a relationship of partners or parties to a joint venture or to constitute the Researcher or Teva an agent, employee or a legal representative of the other party and neither party shall have power or authority to act on behalf of the other party or to bind the other party in any manner whatsoever. 10. ASSIGNMENT 10.1. The rights of Teva under this Agreement shall inure to its successors and assigns. Teva shall be entitled, at any time, to assign this Agreement to an affiliate of Teva provided such successor or assign of Teva shall undertake all of the obligations of Teva hereunder. The rights of Researcher under this Agreement shall not be assignable in whole or in part without the prior written permission of Teva. 11. SEVERABILITY 11.1. Should any part or provision of this Research Agreement be held unenforceable or in conflict with the applicable laws or regulations of any applicable jurisdiction, the invalid or unenforceable part or provision shall, provided that it does not go the essence of this Agreement, be replaced with a revision which accomplishes, to the extent possible, the original commercial purpose of such part or provision in a valid and enforceable manner, and the balance of this Research Agreement shall remain in full force and effect and binding upon the Parties hereto. 12. NO WAIVER 12.1. No waiver by any Party hereto, whether express or implied, of its rights under any provision of this Research Agreement shall constitute a waiver of such Party s rights under such provisions at any other time or a waiver of such Party s rights under any other provision of this Research Agreement. No failure by any Party hereto to take any action against any breach of this Research Agreement or default by another party hereto shall constitute a waiver of the former Party s rights to enforce any provision of this Research Agreement or to take action against such breach or default or any subsequent breach or default by such other Party. 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 14 of 17

13. GOVERNING LAW AND JURISDICTION 13.1. This Research Grant Agreement shall be governed by and construed in accordance with the laws of Israel, without giving effect to its principles of conflicts of law that direct that the laws of another jurisdiction apply and the parties hereto hereby submit to the exclusive jurisdiction of the competent courts in Petach Tiqva, Israel. 14. ENTIRE AGREEMENT 14.1. This Research Agreement constitutes the entire agreement between the Parties hereto in respect of the subject-matter hereof, and supersede all prior agreements or understandings between the parties relating to the subject-matter hereof and this Research Agreement may be amended only by a written document signed by the Parties hereto. 15. NOTICES 15.1. All notices and other communications required or permitted hereunder or necessary in connection herewith shall be in writing and shall be deemed to have been given when hand delivered, sent by facsimile or mailed by registered or certified mail, as follows (provided that notice of change of address shall be deemed given only when received): If to Teva, to: Guy J Rosenthal, PhD Manager, Global Academic Affairs and R&D Networks Email: Guy.Rosenthal@teva.co.il With a copy to: Efrat Shalom-Berensohn, LL.M Executive Counsel, Global R&D Corporate Legal Department Email: Efrat.Shalom-Berensohn @teva.co.il If to Researcher, to: Attention: Telephone: Facsimile: Email: 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 15 of 17

16. COUNTERPARTS 16.1. This Research Grant Agreement shall become binding when any one or more counterparts hereof, individually or taken together, bear the signatures of both parties. Each counterpart shall be deemed an original as against any party whose signature appears thereon, but all counterparts hereof shall constitute but one and the same instrument. IN WITNESS WHEREOF the parties to this Research Grant Agreement have signed and executed this Research Grant Agreement as of the last signature date set forth below. TEVA PHARMACEUTICAL INDUSTRIES LTD. Institution's Name signature: signature: name: name: designation: designation: signature: name: designation: date:, 2014 date:, 2014 Investigator Name signature: name: designation: date:, 2014 Student Name signature: name: designation: date:, 2014 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 16 of 17

ANNEX A TO THE RESEARCH AGREEMENT Research Plan 16 Basel St., Petach Tiqva, Israel. 49131 Tel: +972.3.9148534 Fax. +972.3.9267862 www.tevapharm.com Page 17 of 17